18 June 2021
4basebio UK
Societas
("4basebio" or the "Company")
Annual General
Meeting 2021 ("AGM")
Following the UK government announcement on 14 June 2021 that lockdown measures will not be
withdrawn by the time of the AGM, the Company confirms that it
intends to hold its 2021 AGM with only the minimum number of
shareholders present as required to form a quorum under the
Company's Articles of Association, and who (being officers or
employees of the Company) are essential for the business of the AGM
to be conducted.
As set out in the notice of meeting, the AGM will be held on
30 June 2021 at 9.00am. In view of the continuing risk posed by
COVID-19 and having regard to their own safety and that of others,
shareholders and their representatives are respectfully asked not
to seek to attend the AGM in person. To ensure the safety of the
limited number of people whose attendance is essential, we do not
propose to allow other shareholders or their representatives
to gain access to the AGM venue on the day.
In order to ensure shareholders' votes are counted, despite
these restrictions, the Board strongly encourages shareholders to
exercise their right to vote by appointing the chairman of the AGM
as their proxy to vote at the AGM in accordance with their
instructions. To appoint a proxy, please complete the form of proxy
and send it to our registrar, Computershare Investor Services PLC.
CREST members who wish to appoint a proxy or proxies for the AGM
(and any adjournment(s) thereof) through the CREST electronic proxy
appointment service may do so by using the procedures described in
the CREST Manual (available via www.euroclear.com). Proxy
appointments must be received by Computershare Investor Services
PLC no later than 9:00am on
28 June 2021. If two or more valid
forms of proxy are delivered in respect of the same share, the one
which was delivered last (regardless of its date or the date of its
execution) will be valid. Further details are set out in the notice
of meeting and in the form of proxy.
We, as your Board, are committed to open dialogue with our
shareholders and remain very mindful of ensuring that shareholders
have an opportunity to engage with us. Shareholders are encouraged
to submit questions in advance of the AGM or raise matters of
concern as a shareholder by emailing the Company Secretary using
the email address provided in the notice of meeting. Answers to
questions that are of common interest will be published on the
Company's website. Also, as previously announced, the AGM
will be followed by a presentation from the Company through the
Investor Meet Company platform on 1 July
2021 at 10.00am. Investors can
sign up to Investor Meet Company for free and register interest
here:
https://www.investormeetcompany.com/4basebio-uk-societas/register-investor
For further enquiries, please
contact:
4basebio UK
Societas |
+44 (0)12 2396
7943 |
Heikki Lanckriet,
CEO |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser) |
+44 (0)20 7213
0880 |
Jo Turner / Sandy
Jamieson |
|
|
|
finnCap Ltd
(Broker) |
|
Geoff Nash/Richard
Chambers/Charlotte Sutcliffe |
+44 (0)20 7220
0500 |
|
|
Walbrook
PR |
+44 (0)20 7933
8780 |
Anna Dunphy / Paul McManus |
Mob: +44
(0)7876 441 001 / +44 (0)7980 541 893 |
|
|
|
Notes to Editors
4basebio (AIM: 4BB) is a specialist life sciences group focused
on therapeutic DNA for gene therapies and DNA vaccines and
providing solutions for effective and safe delivery of these DNA
based products to patients. It is the intention of the Company to
become a market leader in the manufacture and supply of high
purity, synthetic DNA for research, therapeutic and pharmacological
use. The immediate objectives of 4bb are to validate and scale its
DNA synthesis and advance its collaborations to facilitate the
functional validation of its DNA based products and gene delivery
solutions.
The Company divested from 4basebio AG (“4bb AG”), a German
company listed on the Prime Standard segment of the Frankfurt Stock
Exchange, following the disposal by 4bb AG (then named Expedeon AG)
of its proteomics and immunology business to AIM-quoted Abcam plc
in January 2020 for €120million.
Following the disposal, 4bb AG retained its genomics business which
owned and licensed certain intellectual property including its
proprietary, patent-protected technology, TruePrime™. This is the
foundation for building the Company’s synthetic DNA manufacturing
business which 4bb AG transferred to the Company along with funding
to continue the Company’s development and investment.